Finding new ways to treat cerebral amyloid angiopathy in Alzheimer's disease
Official title: VCID CWOW: Identifying Novel Targets to Treat Cerebral Amyloid Angiopathy
Funded at Jackson Laboratory · NIH-11019618 · Data updated 2026-11-12
This study is looking for new ways to treat cerebral amyloid angiopathy (CAA), which is linked to Alzheimer's disease, by exploring how certain proteins and genes affect brain health, with the hope of finding better treatments that can help improve thinking and memory for people with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $5,949,022 |
| NIH project number | 1RF1NS139948-01 |
| Project ID | NIH-11019618 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those with the APOE4 genotype.
✕Less likely to help
Patients with non-Alzheimer's forms of dementia or those without any genetic predisposition to Alzheimer's may not benefit from this research.
What this research studies
This research aims to identify new therapeutic targets for treating cerebral amyloid angiopathy (CAA), a condition that contributes to Alzheimer's disease and related dementias. The study will investigate the interactions between amyloid deposition, tau pathology, and genetic factors like the APOE4 allele, which is known to increase the risk of Alzheimer's. By focusing on the cerebrovascular health and the breakdown of the blood-brain barrier, the research seeks to develop treatments that address multiple aspects of Alzheimer's disease. Patients may benefit from innovative therapies that improve cognitive function and overall brain health.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for patients with Alzheimer's disease and related dementias.
How similar studies have gone: Previous research has shown promise in targeting cerebrovascular health in Alzheimer's disease, but this specific approach to CAA is relatively novel.
Where this research is happening
-
Jackson Laboratory
Bar Harbor, United States Active
Researchers
- Principal investigator: Howell, Gareth R — Jackson Laboratory
- Study coordinator: Howell, Gareth R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.